MedTrace Logo

Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis

NCT02326935 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-05-22

No results posted yet for this study

Summary

The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.

Conditions

Interventions

BIOLOGICAL

Autologous adipose derived mesenchymal cells

Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.

Sponsors & Collaborators

  • American CryoStem Corporation

    lead INDUSTRY

Principal Investigators

  • Louis A Cona, MD · The Da Vinci Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-05-18
Completion
2018-05-18

Countries

  • Cayman Islands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02326935 on ClinicalTrials.gov